Login | Sitemap | Disclaimer | About CNSforum | Contact Us Lundbeck Institute Educational Resources Clinical Resources Patient Websites Publications Community Patients with probable AD in mild to moderate stage defined as MMSE 10 to 27, with a total Neuropsychiatric Inventory (NPI) score greater than 11 points arising from at least three domains of behavior. No prior exposure to a cholinesterase inhibitor was allowed. Open label phase I with donepezil 5mg/day then 10mg/day over 6 weeks, followed by a randomized placebo-controlled double-blind phase II for a further 6 weeks.
